List of Tables
    Table 1. Targeted Drugs for Multiple Myeloma Market Opportunities & Trends in Global Market
    Table 2. Targeted Drugs for Multiple Myeloma Market Drivers in Global Market
    Table 3. Targeted Drugs for Multiple Myeloma Market Restraints in Global Market
    Table 4. Key Players of Targeted Drugs for Multiple Myeloma in Global Market
    Table 5. Top Targeted Drugs for Multiple Myeloma Players in Global Market, Ranking by Revenue (2021)
    Table 6. Global Targeted Drugs for Multiple Myeloma Revenue by Companies, (US$, Mn), 2017-2022
    Table 7. Global Targeted Drugs for Multiple Myeloma Revenue Share by Companies, 2017-2022
    Table 8. Global Companies Targeted Drugs for Multiple Myeloma Product Type
    Table 9. List of Global Tier 1 Targeted Drugs for Multiple Myeloma Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 10. List of Global Tier 2 and Tier 3 Targeted Drugs for Multiple Myeloma Companies, Revenue (US$, Mn) in 2021 and Market Share
    Table 11. By Type – Global Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2021 & 2028
    Table 12. By Type - Targeted Drugs for Multiple Myeloma Revenue in Global (US$, Mn), 2017-2022
    Table 13. By Type - Targeted Drugs for Multiple Myeloma Revenue in Global (US$, Mn), 2023-2028
    Table 14. By Application – Global Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2021 & 2028
    Table 15. By Application - Targeted Drugs for Multiple Myeloma Revenue in Global (US$, Mn), 2017-2022
    Table 16. By Application - Targeted Drugs for Multiple Myeloma Revenue in Global (US$, Mn), 2023-2028
    Table 17. By Region – Global Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2021 & 2028
    Table 18. By Region - Global Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), 2017-2022
    Table 19. By Region - Global Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), 2023-2028
    Table 20. By Country - North America Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 21. By Country - North America Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 22. By Country - Europe Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 23. By Country - Europe Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 24. By Region - Asia Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 25. By Region - Asia Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 26. By Country - South America Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 27. By Country - South America Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 28. By Country - Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2022
    Table 29. By Country - Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2023-2028
    Table 30. Celgene Corporate Summary
    Table 31. Celgene Targeted Drugs for Multiple Myeloma Product Offerings
    Table 32. Celgene Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 33. Exova Corporate Summary
    Table 34. Exova Targeted Drugs for Multiple Myeloma Product Offerings
    Table 35. Exova Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 36. Natco Pharma Corporate Summary
    Table 37. Natco Pharma Targeted Drugs for Multiple Myeloma Product Offerings
    Table 38. Natco Pharma Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 39. Intas Pharmaceuticals Corporate Summary
    Table 40. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offerings
    Table 41. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 42. Indiabulls Pharmaceutical Corporate Summary
    Table 43. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offerings
    Table 44. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 45. Cipla Corporate Summary
    Table 46. Cipla Targeted Drugs for Multiple Myeloma Product Offerings
    Table 47. Cipla Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 48. Glenmark Pharmaceuticals Corporate Summary
    Table 49. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product Offerings
    Table 50. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 51. Dr Reddy's Laboratories Corporate Summary
    Table 52. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product Offerings
    Table 53. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 54. Qilu Pharmaceutical Corporate Summary
    Table 55. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offerings
    Table 56. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 57. Chia Tai-Tianqing Corporate Summary
    Table 58. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product Offerings
    Table 59. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 60. Hanson Pharm Corporate Summary
    Table 61. Hanson Pharm Targeted Drugs for Multiple Myeloma Product Offerings
    Table 62. Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 63. Meidakang Huakang Pharmaceutical Corporate Summary
    Table 64. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offerings
    Table 65. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 66. Shandong Kongfu Pharmaceutical Corporate Summary
    Table 67. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product Offerings
    Table 68. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 69. J&J Corporate Summary
    Table 70. J&J Targeted Drugs for Multiple Myeloma Product Offerings
    Table 71. J&J Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 72. Takeda Corporate Summary
    Table 73. Takeda Targeted Drugs for Multiple Myeloma Product Offerings
    Table 74. Takeda Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 75. Amgen Corporate Summary
    Table 76. Amgen Targeted Drugs for Multiple Myeloma Product Offerings
    Table 77. Amgen Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 78. Bristol Myers Squibb Corporate Summary
    Table 79. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product Offerings
    Table 80. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 81. Abbvie Corporate Summary
    Table 82. Abbvie Targeted Drugs for Multiple Myeloma Product Offerings
    Table 83. Abbvie Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 84. Seattle Genetics Corporate Summary
    Table 85. Seattle Genetics Targeted Drugs for Multiple Myeloma Product Offerings
    Table 86. Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 87. Karyopharm Therapeutics Corporate Summary
    Table 88. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product Offerings
    Table 89. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 90. PDL BioPharma Corporate Summary
    Table 91. PDL BioPharma Targeted Drugs for Multiple Myeloma Product Offerings
    Table 92. PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 93. Roche Corporate Summary
    Table 94. Roche Targeted Drugs for Multiple Myeloma Product Offerings
    Table 95. Roche Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 96. Sumitomo Corporate Summary
    Table 97. Sumitomo Targeted Drugs for Multiple Myeloma Product Offerings
    Table 98. Sumitomo Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 99. Merck Corporate Summary
    Table 100. Merck Targeted Drugs for Multiple Myeloma Product Offerings
    Table 101. Merck Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 102. Biogen Corporate Summary
    Table 103. Biogen Targeted Drugs for Multiple Myeloma Product Offerings
    Table 104. Biogen Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 105. Schering-Plough Corporate Summary
    Table 106. Schering-Plough Targeted Drugs for Multiple Myeloma Product Offerings
    Table 107. Schering-Plough Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 108. Glaxo Corporate Summary
    Table 109. Glaxo Targeted Drugs for Multiple Myeloma Product Offerings
    Table 110. Glaxo Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
    Table 111. Chiron Corporate Summary
    Table 112. Chiron Targeted Drugs for Multiple Myeloma Product Offerings
    Table 113. Chiron Targeted Drugs for Multiple Myeloma Revenue (US$, Mn), (2017-2022)
List of Figures
    Figure 1. Targeted Drugs for Multiple Myeloma Segment by Type in 2021
    Figure 2. Targeted Drugs for Multiple Myeloma Segment by Application in 2021
    Figure 3. Global Targeted Drugs for Multiple Myeloma Market Overview: 2021
    Figure 4. Key Caveats
    Figure 5. Global Targeted Drugs for Multiple Myeloma Market Size: 2021 VS 2028 (US$, Mn)
    Figure 6. Global Targeted Drugs for Multiple Myeloma Revenue, 2017-2028 (US$, Mn)
    Figure 7. The Top 3 and 5 Players Market Share by Targeted Drugs for Multiple Myeloma Revenue in 2021
    Figure 8. By Type - Global Targeted Drugs for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 9. By Application - Global Targeted Drugs for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 10. By Region - Global Targeted Drugs for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 11. By Country - North America Targeted Drugs for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 12. US Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 13. Canada Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 14. Mexico Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 15. By Country - Europe Targeted Drugs for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 16. Germany Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 17. France Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 18. U.K. Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 19. Italy Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 20. Russia Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 21. Nordic Countries Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 22. Benelux Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 23. By Region - Asia Targeted Drugs for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 24. China Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 25. Japan Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 26. South Korea Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 27. Southeast Asia Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 28. India Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 29. By Country - South America Targeted Drugs for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 30. Brazil Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 31. Argentina Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 32. By Country - Middle East & Africa Targeted Drugs for Multiple Myeloma Revenue Market Share, 2017-2028
    Figure 33. Turkey Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 34. Israel Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 35. Saudi Arabia Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 36. UAE Targeted Drugs for Multiple Myeloma Revenue, (US$, Mn), 2017-2028
    Figure 37. Celgene Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 38. Exova Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 39. Natco Pharma Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 40. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 41. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 42. Cipla Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 43. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 44. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 45. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 46. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 47. Hanson Pharm Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 48. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 49. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 50. J&J Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 51. Takeda Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 52. Amgen Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 53. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 54. Abbvie Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 55. Seattle Genetics Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 56. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 57. PDL BioPharma Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 58. Roche Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 59. Sumitomo Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 60. Merck Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 61. Biogen Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 62. Schering-Plough Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 63. Glaxo Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
    Figure 64. Chiron Targeted Drugs for Multiple Myeloma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)